Rein Therapeutics RNTX
NASDAQ RNTX
$0.60 -0.02 (-3.75%)
As of: Oct 22, 2026 · 11:47 AM EDT

Rein Therapeutics (RNTX) Other Non-Current Liabilities (2016 - 2024)

Updated

Rein Therapeutics (RNTX) reported Other Non-Current Liabilities of $277,000 for Q4 2024.

Analysis

Rein Therapeutics (RNTX) Other Non-Current Liabilities (2016 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,170.86 Bn 1,139.45 Bn 19.71 Bn
2 Johnson & Johnson 639.81 Bn 558.34 Bn 17.26 Bn
3 AbbVie 501.68 Bn 474.79 Bn 12.70 Bn
4 Merck 374.79 Bn 329.16 Bn 12.21 Bn
5 Novartis Ag 302.69 Bn 266.68 Bn 11.24 Bn
6 Astrazeneca 268.27 Bn 241.96 Bn 12.86 Bn
7 Amgen 242.43 Bn 197.83 Bn 7.24 Bn
8 Gilead Sciences 193.38 Bn 167.58 Bn 6.22 Bn
9 Pfizer 172.45 Bn 119.10 Bn 10.94 Bn
10 Rein Therapeutics 40.34 Mn -3.28 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 277,000.00
Jun 30, 2024 116,000.00
Dec 31, 2016 11,000.00
API Access

Rein Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=RNTX&period=max&api_key=YOUR_API_KEY